Pharmaceuticals, Biotechnology and Life Sciences
Don't spend too much on your repeated translations.
Cut costs with Vikler Media. Visit: media.vikler.net
Genflow Biosciences, the only publicly listed longevity company in Europe, has launched a new development program in ophthalmology, focused on advancing a novel gene therapy leveraging its proprietary Centenarian SIRT6...
Moderna reports full-year revenues of $3.2 billion, GAAP net loss of $(3.6) billion and GAAP diluted EPS of $(9.28), and expects 2025 revenue range of $1.5 to 2.5 billion andending...
Micrima, a Bristol-based health tech company, is urging women to give themselves the gift of prioritising knowledge of their breast density this Christmas. Dense breast tissue is a relatively unknown but common breast cancer risk factor, which additionally makes it...
Brenntag, the global market leader in chemicals and ingredients distribution, held a celebration to mark its 150-year anniversary yesterday in...
Over-65s across the UK are set to benefit from potentially life-changing new treatment options for conditions like cancer and cardiovascular...
CARLSBAD, Calif., May 14, 2025 (GLOBE NEWSWIRE) — Natural Alternatives International, Inc. (“NAI”) (Nasdaq: NAII), a leading formulator, manufacturer, and…
Correction: Time of BofA ConferenceSALT LAKE CITY, May 14, 2025 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader…
REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company…
DEER PARK, Ill., May 14, 2025 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative…
Bolstered management team with hires of Chief Executive Officer and Chief Medical Officer with deep biopharmaceutical experienceAnnounced selection of IL15-superagonist…
TORONTO, May 14, 2025 (GLOBE NEWSWIRE) — Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics…
Continued operational excellence leading to acceleration of multiple timelines: ORKA-001, targeting IL-23p19, Phase 1 trial dosing complete, with data expected…
Meaningful and durable increases in functional neutrophils observed over 6-month trial with oral once-daily mavorixafor Majority of physicians and chronic…
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 14, 2025- GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated…
Phase 3 HERO trial of ARD-101 for the treatment of hyperphagia associated with Prader-Willi Syndrome (PWS); data readout expected in…